Works matching IS 01676997 AND DT 2013 AND VI 31 AND IP 5

Results: 40

Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancer.

Published in:

2013

By:

Okamoto, Isamu;
Aoe, Keisuke;
Kato, Terufumi;
Hosomi, Yukio;
Yokoyama, Akira;
Imamura, Fumio;
Kiura, Katsuyuki;
Hirashima, Tomonori;
Nishio, Makoto;
Nogami, Naoyuki;
Okamoto, Hiroaki;
Saka, Hideo;
Yamamoto, Nobuyuki;
Yoshizuka, Naoto;
Sekiguchi, Risa;
Kiyosawa, Kazuhiro;
Nakagawa, Kazuhiko;
Tamura, Tomohide

Publication type:

Journal Article

Erratum to: Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancer.

Published in:

2013

By:

Okamoto, Isamu;
Aoe, Keisuke;
Kato, Terufumi;
Hosomi, Yukio;
Yokoyama, Akira;
Imamura, Fumio;
Kiura, Katsuyuki;
Hirashima, Tomonori;
Nishio, Makoto;
Nogami, Naoyuki;
Okamoto, Hiroaki;
Saka, Hideo;
Yamamoto, Nobuyuki;
Yoshizuka, Naoto;
Sekiguchi, Risa;
Kiyosawa, Kazuhiro;
Nakagawa, Kazuhiko;
Tamura, Tomohide

Publication type:

Journal Article

A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance)

Published in:

2013

By:

Gupta, Pankaj;
Mulkey, Flora;
Hasserjian, Robert;
Sanford, Ben;
Vij, Ravi;
Hurd, David;
Odenike, Olatoyosi;
Bloomfield, Clara;
Owzar, Kouros;
Stone, Richard;
Larson, Richard

Publication type:

Journal Article

Patupilone in patients with pretreated metastatic/locally recurrent colorectal cancer: results of the Phase II CINATRA trial.

Published in:

Investigational New Drugs, 2013, v. 31, n. 5, p. 1339, doi. 10.1007/s10637-013-9990-3

By:

Moorcraft, S.;
Chau, I.;
Peckitt, C.;
Cunningham, D.;
Rao, S.;
Yim, K.;
Walther, A.;
Jackson, C.;
Stamp, G.;
Webb, J.;
Smith, G.;
Gillbanks, A.;
Swanton, C.

Publication type:

Article

Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies.

Published in:

Investigational New Drugs, 2013, v. 31, n. 5, p. 1192, doi. 10.1007/s10637-013-0003-3

By:

Falchook, Gerald;
Fu, Siqing;
Naing, Aung;
Hong, David;
Hu, Wei;
Moulder, Stacy;
Wheler, Jennifer;
Sood, Anil;
Bustinza-Linares, Ernesto;
Parkhurst, Kristin;
Kurzrock, Razelle

Publication type:

Article

Role of IL-8 induced angiogenesis in uveal melanoma.

Published in:

Investigational New Drugs, 2013, v. 31, n. 5, p. 1107, doi. 10.1007/s10637-013-0005-1

By:

Lattanzio, Laura;
Tonissi, Federica;
Torta, Ilaria;
Gianello, Luca;
Russi, Elvio;
Milano, Gerard;
Merlano, Marco;
Lo Nigro, Cristiana

Publication type:

Article

Phase II clinical study of modified FOLFOX7 (intermittent oxaliplatin administration) plus bevacizumab in patients with unresectable metastatic colorectal cancer-CRAFT study.

Published in:

Investigational New Drugs, 2013, v. 31, n. 5, p. 1321, doi. 10.1007/s10637-013-9982-3

By:

Tezuka, Tohru;
Hamada, Chikuma;
Ishida, Hideyuki;
Ooshiro, Mitsuru;
Matsuoka, Hiroshi;
Kawasaki, Shingo;
Mishima, Hideyuki;
Maeda, Kotaro;
Sakamoto, Junichi;
Koda, Keiji

Publication type:

Article

Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner.

Published in:

Investigational New Drugs, 2013, v. 31, n. 5, p. 1169, doi. 10.1007/s10637-013-9968-1

By:

Vlachostergios, Panagiotis;
Hatzidaki, Eleana;
Befani, Christina;
Liakos, Panagiotis;
Papandreou, Christos

Publication type:

Article

The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer.

Published in:

Investigational New Drugs, 2013, v. 31, n. 5, p. 1375, doi. 10.1007/s10637-013-9967-2

By:

Khalil, Mohamed;
Qiao, Wei;
Carlson, Peter;
George, Binsah;
Javle, Milind;
Overman, Michael;
Varadhachary, Gauri;
Wolff, Robert;
Abbruzzese, James;
Fogelman, David

Publication type:

Article

Phase I study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies.

Published in:

Investigational New Drugs, 2013, v. 31, n. 5, p. 1251, doi. 10.1007/s10637-013-9946-7

By:

Schenk, Erin;
Hendrickson, Andrea;
Northfelt, Donald;
Toft, David;
Ames, Matthew;
Menefee, Michael;
Satele, Daniel;
Qin, Rui;
Erlichman, Charles

Publication type:

Article

A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancer.

Published in:

Investigational New Drugs, 2013, v. 31, n. 5, p. 1300, doi. 10.1007/s10637-013-9973-4

By:

Park, K.;
Sohn, J.;
Lee, S.;
Park, J.;
Kang, S.;
Kim, H.;
Park, I.;
Park, Y.;
Im, Y.;
Lee, H.;
Hong, D.;
Park, S.;
Shin, S.;
Kwon, H.;
Seo, J.

Publication type:

Article

Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancer.

Published in:

Investigational New Drugs, 2013, v. 31, n. 5, p. 1275, doi. 10.1007/s10637-013-9941-z

By:

Okamoto, Isamu;
Aoe, Keisuke;
Kato, Terufumi;
Hosomi, Yukio;
Yokoyama, Akira;
Imamura, Fumio;
Kiura, Katsuyuki;
Hirashima, Tomonori;
Nishio, Makoto;
Nogami, Naoyuki;
Okamoto, Hiroaki;
Saka, Hideo;
Yamamoto, Nobuyuki;
Yoshizuka, Naoto;
Sekiguchi, Risa;
Kiyosawa, Kazuhiro;
Nakagawa, Kazuhiko;
Tamura, Tomohide

Publication type:

Article

Sunitinib malate in previously untreated, nonsquamous, non-small cell lung cancer patients over the age of 70 years: Results of a Phase II trial.

Published in:

Investigational New Drugs, 2013, v. 31, n. 5, p. 1330, doi. 10.1007/s10637-013-9985-0

By:

Reynolds, Craig;
Spira, Alexander;
Gluck, Larry;
Mueller, Suzanne;
Zhan, Feng;
Boehm, Kristi;
Asmar, Lina

Publication type:

Article

Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies.

Published in:

Investigational New Drugs, 2013, v. 31, n. 5, p. 1201, doi. 10.1007/s10637-013-0004-2

By:

Kumar, Shaji;
Jett, James;
Marks, Randolph;
Richardson, Ronald;
Quevedo, Fernando;
Moynihan, Timothy;
Croghan, Gary;
Markovic, Svetomir;
Bible, Keith;
Qin, Rui;
Tan, Angelina;
Molina, Julian;
Kaufmann, Scott;
Erlichman, Charles;
Adjei, Alex

Publication type:

Article

Novel bourgeonal fragrance conjugates for the detection of prostate cancer.

Published in:

Investigational New Drugs, 2013, v. 31, n. 5, p. 1151, doi. 10.1007/s10637-013-9943-x

By:

Sturzu, Alexander;
Sheikh, Sumbla;
Echner, Hartmut;
Nägele, Thomas;
Deeg, Martin;
Schwentner, Christian;
Horger, Marius;
Ernemann, Ulrike;
Heckl, Stefan

Publication type:

Article

A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2013, v. 31, n. 5, p. 1182, doi. 10.1007/s10637-013-0001-5

By:

Diaz-Padilla, Ivan;
Hirte, Hal;
Oza, Amit;
Clarke, Blaise;
Cohen, Brenda;
Reedjik, Michael;
Zhang, Tong;
Kamel-Reid, Suzanne;
Ivy, S.;
Hotte, Sebastien;
Razak, Albiruni;
Chen, Eric;
Brana, Irene;
Wizemann, Monika;
Wang, Lisa;
Siu, Lillian;
Bedard, Philippe

Publication type:

Article

Bronchoscopic findings for bevacizumab-related pulmonary hemorrhage in advanced non-small cell lung cancer.

Published in:

2013

By:

Okamoto, Kunio;
Okamoto, Isamu;
Miyazaki, Masaki;
Tanaka, Kaoru;
Kaneda, Hiroyasu;
Nakagawa, Kazuhiko

Publication type:

Report

Bcl-2 antagonists: a proof of concept for CLL therapy.

Published in:

Investigational New Drugs, 2013, v. 31, n. 5, p. 1384, doi. 10.1007/s10637-013-0002-4

By:

Balakrishnan, Kumudha;
Gandhi, Varsha

Publication type:

Article

Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2013, v. 31, n. 5, p. 1236, doi. 10.1007/s10637-013-9942-y

By:

Sessa, Cristiana;
Conte, Gianluca;
Christinat, Alexandre;
Cresta, Sara;
Perotti, Antonella;
Gallerani, Elisa;
Lardelli, Pilar;
Kahatt, Carmen;
Alfaro, Vicente;
Iglesias, Jorge;
Fernández-Teruel, Carlos;
Gianni, Luca

Publication type:

Article

A phase II study of combined VEGF inhibitor (bevacizumab+sorafenib) in patients with metastatic breast cancer: Hoosier Oncology Group Study BRE06-109.

Published in:

Investigational New Drugs, 2013, v. 31, n. 5, p. 1307, doi. 10.1007/s10637-013-9976-1

By:

Mina, Lida;
Yu, Menggang;
Johnson, Cynthia;
Burkhardt, Cyndi;
Miller, Kathy;
Zon, Robin

Publication type:

Article

Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors.

Published in:

2013

By:

Yoo, Changhoon;
Ryu, Min-Hee;
Ryoo, Baek-Yeol;
Beck, Mo;
Kang, Yoon-Koo

Publication type:

Report

Genotype-dependent cooperation of ionizing radiation with BRAF inhibition in BRAF V600E-mutated carcinomas.

Published in:

Investigational New Drugs, 2013, v. 31, n. 5, p. 1136, doi. 10.1007/s10637-013-9928-9

By:

Dasgupta, Tina;
Haas-Kogan, Daphne;
Yang, Xiaodong;
Olow, Aleksandra;
Yang, Daniel;
Gragg, Ashley;
Orloff, Lisa;
Yom, Sue

Publication type:

Article

Excessive MET signaling causes acquired resistance and addiction to MET inhibitors in the MKN45 gastric cancer cell line.

Published in:

Investigational New Drugs, 2013, v. 31, n. 5, p. 1158, doi. 10.1007/s10637-013-9959-2

By:

Funakoshi, Yohei;
Mukohara, Toru;
Tomioka, Hideo;
Ekyalongo, Roudy;
Kataoka, Yu;
Inui, Yumiko;
Kawamori, Yuriko;
Toyoda, Masanori;
Kiyota, Naomi;
Fujiwara, Yutaka;
Minami, Hironobu

Publication type:

Article

Effect of small angiokinase inhibitor nintedanib (BIBF 1120) on QT interval in patients with previously untreated, advanced renal cell cancer in an open-label, phase II study.

Published in:

Investigational New Drugs, 2013, v. 31, n. 5, p. 1283, doi. 10.1007/s10637-013-9962-7

By:

Eisen, Tim;
Shparyk, Yaroslav;
Macleod, Nicholas;
Jones, Robert;
Wallenstein, Gudrun;
Temple, Graham;
Khder, Yasser;
Dallinger, Claudia;
Studeny, Matus;
Loembe, Arsene-Bienvenu;
Bondarenko, Igor

Publication type:

Article

A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2.

Published in:

Investigational New Drugs, 2013, v. 31, n. 5, p. 1294, doi. 10.1007/s10637-013-9972-5

By:

Nakai, Yousuke;
Isayama, Hiroyuki;
Ijichi, Hideaki;
Sasaki, Takashi;
Takahara, Naminatsu;
Ito, Yukiko;
Matsubara, Saburo;
Uchino, Rie;
Yagioka, Hiroshi;
Arizumi, Toshihiko;
Hamada, Tsuyoshi;
Miyabayashi, Koji;
Mizuno, Suguru;
Yamamoto, Keisuke;
Kogure, Hirofumi;
Yamamoto, Natsuyo;
Hirano, Kenji;
Sasahira, Naoki;
Tateishi, Keisuke;
Tada, Minoru

Publication type:

Article

Erratum to: Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancer.

Published in:

2013

By:

Okamoto, Isamu;
Aoe, Keisuke;
Kato, Terufumi;
Hosomi, Yukio;
Yokoyama, Akira;
Imamura, Fumio;
Kiura, Katsuyuki;
Hirashima, Tomonori;
Nishio, Makoto;
Nogami, Naoyuki;
Okamoto, Hiroaki;
Saka, Hideo;
Yamamoto, Nobuyuki;
Yoshizuka, Naoto;
Sekiguchi, Risa;
Kiyosawa, Kazuhiro;
Nakagawa, Kazuhiko;
Tamura, Tomohide

Publication type:

Correction Notice

A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer.

Published in:

Investigational New Drugs, 2013, v. 31, n. 5, p. 1257, doi. 10.1007/s10637-013-9947-6

By:

Garrido-Laguna, I.;
McGregor, K.;
Wade, M.;
Weis, J.;
Gilcrease, W.;
Burr, L.;
Soldi, R.;
Jakubowski, L.;
Davidson, C.;
Morrell, G.;
Olpin, J.;
Boucher, K.;
Jones, D.;
Sharma, S.

Publication type:

Article

In silico analysis of the amido phosphoribosyltransferase inhibition by PY873, PY899 and a derivative of isophthalic acid.

Published in:

2013

By:

Batool, Sidra;
Nawaz, Muhammad;
Kamal, Mohammad

Publication type:

Report

Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study.

Published in:

Investigational New Drugs, 2013, v. 31, n. 5, p. 1345, doi. 10.1007/s10637-013-9991-2

By:

Hyams, David;
Chan, Arlene;
Oliveira, Celia;
Snyder, Raymond;
Vinholes, Jeferson;
Audeh, M.;
Alencar, Victor;
Lombard, Janine;
Mookerjee, Bijoyesh;
Xu, John;
Brown, Kathryn;
Klein, Paula

Publication type:

Article

A Phase I Study of the combination of oxaliplatin/docetaxel and vandetanib for the treatment of advanced gastroesophageal cancer.

Published in:

Investigational New Drugs, 2013, v. 31, n. 5, p. 1244, doi. 10.1007/s10637-013-9945-8

By:

Halmos, Balazs;
Jia, Yuxia;
Bokar, Joseph;
Fu, Pingfu;
Adelstein, David;
Juergens, Rosalyn;
Rodal, Mary;
Dowlati, Afshin

Publication type:

Article

Polycationic calixarene PTX013, a potent cytotoxic agent against tumors and drug resistant cancer.

Published in:

Investigational New Drugs, 2013, v. 31, n. 5, p. 1142, doi. 10.1007/s10637-013-9932-0

By:

Dings, Ruud;
Levine, Joseph;
Brown, Susan;
Astorgues-Xerri, Lucile;
MacDonald, John;
Hoye, Thomas;
Raymond, Eric;
Mayo, Kevin

Publication type:

Article

Digalloylresveratrol, a novel resveratrol analog inhibits the growth of human pancreatic cancer cells.

Published in:

Investigational New Drugs, 2013, v. 31, n. 5, p. 1115, doi. 10.1007/s10637-013-0009-x

By:

Saiko, Philipp;
Graser, Geraldine;
Giessrigl, Benedikt;
Steinmann, Marie-Thérèse;
Schuster, Heike;
Lackner, Andreas;
Grusch, Michael;
Krupitza, Georg;
Jaeger, Walter;
Somepalli, Venkateswarlu;
Golakoti, Trimurtulu;
Fritzer-Szekeres, Monika;
Szekeres, Thomas

Publication type:

Article

Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor.

Published in:

Investigational New Drugs, 2013, v. 31, n. 5, p. 1265, doi. 10.1007/s10637-012-9910-y

By:

Ito, Tetsuhide;
Okusaka, Takuji;
Nishida, Toshirou;
Yamao, Kenji;
Igarashi, Hisato;
Morizane, Chigusa;
Kondo, Shunsuke;
Mizuno, Nobumasa;
Hara, Kazuo;
Sawaki, Akira;
Hashigaki, Satoshi;
Kimura, Nobuyuki;
Murakami, Mami;
Ohki, Emiko;
Chao, Richard;
Imamura, Masayuki

Publication type:

Article

Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck.

Published in:

Investigational New Drugs, 2013, v. 31, n. 5, p. 1207, doi. 10.1007/s10637-013-9933-z

By:

Machiels, Jean-Pascal;
Kaminsky, Marie-Christine;
Keller, Ulrich;
Brümmendorf, Tim;
Goddemeier, Thomas;
Forssmann, Ulf;
Delord, Jean-Pierre

Publication type:

Article

A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance).

Published in:

Investigational New Drugs, 2013, v. 31, n. 5, p. 1311, doi. 10.1007/s10637-013-9978-z

By:

Gupta, Pankaj;
Mulkey, Flora;
Hasserjian, Robert;
Sanford, Ben;
Vij, Ravi;
Hurd, David;
Odenike, Olatoyosi;
Bloomfield, Clara;
Owzar, Kouros;
Stone, Richard;
Larson, Richard

Publication type:

Article

Vascular disrupting effect of CKD-516: preclinical study using DCE-MRI.

Published in:

Investigational New Drugs, 2013, v. 31, n. 5, p. 1097, doi. 10.1007/s10637-012-9915-6

By:

Kim, Kyung;
Lee, Jeong;
Jeon, Yong;
Lee, In;
Choi, YoonSeok;
Park, Jisuk;
Kiefer, Berthold;
Kim, Chin;
Han, Joon;
Choi, Byung

Publication type:

Article

Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA.

Published in:

Investigational New Drugs, 2013, v. 31, n. 5, p. 1125, doi. 10.1007/s10637-013-9923-1

By:

Marchetti, Serena;
Pluim, Dick;
Eijndhoven, Monique;
Tellingen, Olaf;
Mazzanti, Roberto;
Beijnen, Jos;
Schellens, Jan

Publication type:

Article

Erratum to: Vascular disrupting effect of CKD-516: preclinical study using DCE-MRI.

Published in:

2013

By:

Kim, Kyung;
Lee, Jeong;
Jeon, Yong;
Lee, In;
Choi, YoonSeok;
Park, Jisuk;
Kiefer, Berthold;
Kim, Chin;
Han, Joon;
Choi, Byung

Publication type:

Correction Notice

An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer.

Published in:

Investigational New Drugs, 2013, v. 31, n. 5, p. 1228, doi. 10.1007/s10637-013-9938-7

By:

Brady, Joanne;
Corrie, Pippa;
Chau, Ian;
Digumarti, Raghunadharao;
Adams, Laurel;
Botbyl, Jeffrey;
Laubscher, Kevin;
Midgley, Rachel;
Mallath, Mohandas

Publication type:

Article

Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome.

Published in:

Investigational New Drugs, 2013, v. 31, n. 5, p. 1217, doi. 10.1007/s10637-013-9937-8

By:

Gojo, Ivana;
Perl, Alexander;
Luger, Selina;
Baer, Maria;
Norsworthy, Kelly;
Bauer, Kenneth;
Tidwell, Michael;
Fleckinger, Stephanie;
Carroll, Martin;
Sausville, Edward

Publication type:

Article